DHG Pharmaceutical JSC Cash Flow Conversion Efficiency
DHG Pharmaceutical JSC cash flow conversion efficiency. Based on the latest financial reports, DHG Pharmaceutical JSC (DHG) has a cash flow conversion efficiency ratio of 0.063x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₫214.23 Billion ≈ $8.14 Million USD) by net assets (₫3.42 Trillion ≈ $129.89 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of DHG Pharmaceutical JSC (2019–2025)
Cash flow conversion efficiency of DHG Pharmaceutical JSC from 2019 to 2025. This chart illustrates how DHG Pharmaceutical JSC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View DHG share price today for real-time trading data and today's change.
DHG Pharmaceutical JSC Cash Flow Conversion Ratio Explained
DHG Pharmaceutical JSC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
DHG Pharmaceutical JSC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DHG Pharmaceutical JSC ranked by their cash flow conversion efficiency. Also see DHG market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ackerstein Group Ltd
TA:ACKR
|
0.042x |
|
NH SPAC 8
KQ:225570
|
-0.014x |
|
Enity
ST:ENITY
|
0.430x |
|
First Tractor Company Limited
F:FTP
|
0.097x |
|
Tokmanni Group Oyj
HE:TOKMAN
|
-0.003x |
|
Shanthi Gears Limited
NSE:SHANTIGEAR
|
0.116x |
|
Solusi Bangun Indonesia Tbk PT
JK:SMCB
|
0.014x |
|
ATN International Inc
NASDAQ:ATNI
|
0.033x |
Annual Cash Flow Conversion Efficiency for DHG Pharmaceutical JSC (2019–2025)
The table below shows the annual cash flow conversion efficiency of DHG Pharmaceutical JSC from 2019 to 2025. Review DHG Pharmaceutical JSC (DHG) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₫4.18 Trillion ≈ $158.91 Million |
₫1.21 Trillion ≈ $46.09 Million |
0.290x | -9.87% |
| 2024-12-31 | ₫4.09 Trillion ≈ $155.58 Million |
₫1.32 Trillion ≈ $50.06 Million |
0.322x | +457.94% |
| 2023-12-31 | ₫4.85 Trillion ≈ $184.38 Million |
₫279.88 Billion ≈ $10.63 Million |
0.058x | -72.54% |
| 2022-12-31 | ₫4.29 Trillion ≈ $163.05 Million |
₫901.28 Billion ≈ $34.24 Million |
0.210x | +76.07% |
| 2021-12-31 | ₫3.79 Trillion ≈ $144.12 Million |
₫452.44 Billion ≈ $17.19 Million |
0.119x | -48.49% |
| 2020-12-31 | ₫3.57 Trillion ≈ $135.56 Million |
₫826.17 Billion ≈ $31.39 Million |
0.232x | -6.70% |
| 2019-12-31 | ₫3.38 Trillion ≈ $128.33 Million |
₫838.24 Billion ≈ $31.85 Million |
0.248x | -- |
About DHG Pharmaceutical JSC
DHG Pharmaceutical Joint Stock Company, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Vietnam. The company offers antibiotic, analgesic and antipyretic, respiratory, nutrition, musculoskeletal, gastrointestinal and hepatobiliary, nervous and ophthalmic, cardiovascular and diabetic, dermatology, and beauty care products. It also manufactures and … Read more